Polo-like kinase 4's critical role in cancer development and strategies for Plk4-targeted therapy

X Zhang, C Wei, H Liang, L Han - Frontiers in Oncology, 2021 - frontiersin.org
Polo-like kinases (Plks) are critical regulatory molecules during the cell cycle process. This
family has five members: Plk1, 2, 3, 4, and 5. Plk4 has been identified as a master regulator …

Centrosome dysfunction: a link between senescence and tumor immunity

Q Wu, B Li, L Liu, S Sun, S Sun - Signal Transduction and Targeted …, 2020 - nature.com
Centrosome aberrations are hallmarks of human cancers and contribute to the senescence
process. Structural and numerical centrosome abnormalities trigger mitotic errors, cellular …

CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma

C Gu, W Wang, X Tang, T Xu, Y Zhang, M Guo, R Wei… - Molecular Cancer, 2021 - Springer
Background Multiple myeloma (MM) is still incurable and characterized by clonal expansion
of plasma cells in the bone marrow (BM). Therefore, effective therapeutic interventions must …

Targeting centrosome amplification, an Achilles' heel of cancer

D Sabat-Pośpiech… - Biochemical Society …, 2019 - portlandpress.com
Due to cell-cycle dysregulation, many cancer cells contain more than the normal compliment
of centrosomes, a state referred to as centrosome amplification (CA). CA can drive …

The fate of extra centrosomes in newly formed tetraploid cells: should I stay, or should I go?

M Bloomfield, D Cimini - Frontiers in Cell and Developmental Biology, 2023 - frontiersin.org
An increase in centrosome number is commonly observed in cancer cells, but the role
centrosome amplification plays along with how and when it occurs during cancer …

PLK4: a promising target for cancer therapy

Y Zhao, X Wang - Journal of cancer research and clinical oncology, 2019 - Springer
Purpose Polo-like kinase 4 (PLK4) is a serine/threonine protein kinase that regulates
centriole duplication. PLK4 deregulation causes centrosome number abnormalities, mitotic …

Therapeutic potential of targeting polo-like kinase 4

Q Lei, Q Yu, N Yang, Z ** more effective therapies against the
most aggressive, triple-negative, breast cancer (TNBC) subtype. In our previous studies, we …